Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.20452/pamw.15796 http://scihub22266oqcxt.onion/10.20452/pamw.15796 33544564!ä!33544564 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pol+Arch+Intern+Med 2021 ; 131 (3): 226-232 Nephropedia Template TP {{tp|p=33544564|t=2021. Inflammatory bowel disease is associated with higher seroprevalence rates of antibodies against SARS-CoV-2 |pdf=|usr=}}{{33544564}} gab.com Text Inflammatory bowel disease is associated with higher seroprevalence rates of antibodies against SARS-CoV-2 JO: Pol Arch Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=33544564 #FOAvip INTRODUCTION: According to the current data, there has been no increase in the incidence of COVID?19 in patients with inflammatory bowel disease (IBD). OBJECTIVES: The available data are based on symptomatic cases and do not include the asymptomatic ones. To measure the exact infection rate, we initiated a study that aimed to assess the seroprevalence of anti-SARS?CoV?2 antibodies in IBD. PATIENTS AND METHODS: A total of 864 individuals were enrolled in the study, including 432 patients with IBD (290 with Crohn disease and 142 with ulcerative colitis) and 432 controls without IBD (healthcare professionals) matched for age and sex. Serum samples were prospectively collected, and the presence of anti-SARS?CoV?2 immunoglobulin (Ig) G and IgM + IgA antibodies were measured using the enzyme?linked immunoassay method (Vircell Microbiologists). RESULTS: A significantly higher percentage of positive results for anti-SARS?CoV?2 antibodies, both in the IgG and IgM + IgA class, was found in patients with IBD (4.6% and 6%, respectively, compared with 1.6% and 1.1%, respectively, in controls; both P values <0.05). No patient had symptomatic COVID?19. There was no association among patients' age, sex, drugs used for IBD, or disease activity and the occurrence of IgG antibodies. CONCLUSION: Patients with IBD may be at higher risk of developing SARS?CoV?2 infection, defined as the presence of elevated levels of anti-SARS?CoV?2 IgG antibodies, but not of having a symptomatic and / or severe course of COVID?19 compared with healthcare professionals without IBD. Twit Text FOAVip Inflammatory bowel disease is associated with higher seroprevalence rates of antibodies against SARS-CoV-2 ????Pol Arch Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=33544564 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33544564 #FOAvip English Wikipedia <ref>{{Cite pmid|33544564}}</ref> Inflammatory bowel disease is associated with higher seroprevalence rates of antibodies against SARS-CoV-2 #MMPMID33544564 Lodyga M; Maciejewska K; Eder P; Waszak K; Stawczyk-Eder K; Michalak M; Dobrowolska A; Wisniewska-Jarosinska M; Gasiorowska A; Cicha M; Wierzba W; Rydzewska G Pol Arch Intern Med 2021[Mar]; 131 (3): 226-232 PMID33544564show ga INTRODUCTION: According to the current data, there has been no increase in the incidence of COVID?19 in patients with inflammatory bowel disease (IBD). OBJECTIVES: The available data are based on symptomatic cases and do not include the asymptomatic ones. To measure the exact infection rate, we initiated a study that aimed to assess the seroprevalence of anti-SARS?CoV?2 antibodies in IBD. PATIENTS AND METHODS: A total of 864 individuals were enrolled in the study, including 432 patients with IBD (290 with Crohn disease and 142 with ulcerative colitis) and 432 controls without IBD (healthcare professionals) matched for age and sex. Serum samples were prospectively collected, and the presence of anti-SARS?CoV?2 immunoglobulin (Ig) G and IgM + IgA antibodies were measured using the enzyme?linked immunoassay method (Vircell Microbiologists). RESULTS: A significantly higher percentage of positive results for anti-SARS?CoV?2 antibodies, both in the IgG and IgM + IgA class, was found in patients with IBD (4.6% and 6%, respectively, compared with 1.6% and 1.1%, respectively, in controls; both P values <0.05). No patient had symptomatic COVID?19. There was no association among patients' age, sex, drugs used for IBD, or disease activity and the occurrence of IgG antibodies. CONCLUSION: Patients with IBD may be at higher risk of developing SARS?CoV?2 infection, defined as the presence of elevated levels of anti-SARS?CoV?2 IgG antibodies, but not of having a symptomatic and / or severe course of COVID?19 compared with healthcare professionals without IBD. |COVID-19/*epidemiology[MESH] |Colitis, Ulcerative[MESH] |Humans[MESH] |Inflammatory Bowel Diseases/*epidemiology[MESH] |SARS-CoV-2[MESH]Inflammatory bowel disease is associated with higher seroprevalence ra(epmc).pdf DeepDyve Pubget Overpricing